Registro:

Referencias:

• Burri, C., Brun, R., Human African try-panosomiasis (2003) Manson's tropical diseases, pp. 1303-1323. , G.C. Cook and A.I. Zumla, editors. 21st edition. W.B. Saunders/Elsevier. Edinburgh, United Kingdom
• Human African try-panosomiasis (sleeping sickness): Epidemiological update (2006) Wkly. Epidemiol. Rec, 81, pp. 71-80
• Radwanska, M., The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense (2002) Am. J. Trop. Med. Hyg, 67, pp. 684-690
• Radwanska, M., Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense (2002) Am. J. Trop. Med. Hyg, 67, pp. 289-295
• Magnus, E., Vervoort, T., and Van Meirvenne, N. 1978. A card-agglutination test with stained try-panosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann. Soc. Belg. Med. Trop. 58:169-176; Deborggraeve, S., Molecular dipstick test for diagnosis of sleeping sickness (2006) J. Clin. Microbiol, 44, pp. 2884-2889
• Xong, H.V., A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense (1998) Cell, 95, pp. 839-846
• Welburn, S.C., Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene (2001) Lancet, 358, pp. 2017-2019
• Lejon, V., IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test (2002) Trop. Med. Int. Health, 7, pp. 685-692
• Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee (1998) World Health Organ. Tech. Rep. Ser, 881, pp. 1-114
• Young, C., Losikoff, P., Chawla, A., Glasser, L., Forman, E., Transfusion-acquired Trypanosoma cruzi infection (2007) Transfusion, 47, pp. 540-544
• California, 2006 (2006) MMWR Morb. Mortal. Wkly. Rep, 55, pp. 798-800. , Chagas disease after organ transplantation, Los Angeles
• Gurtler, R.E., Segura, E.L., Cohen, J.E., Congenital transmission of Trypanosoma cruzi infection in Argentina (2003) Emerg. Infect Dis, 9, pp. 29-32
• Benchimol Barbosa, P.R., The oral transmission of Chagas' disease: An acute form of infection responsible for regional outbreaks (2006) Int. J. Cardiol, 112, pp. 132-133
• Tarleton, R.L., Chagas disease: A role for autoimmunity? (2003) Trends Parasitol, 19, pp. 447-451
• Andrade, L.O., Andrews, N.W., The Trypanosoma cruzi-host-cell interplay: Location, invasion, retention (2005) Nat. Rev. Microbiol, 3, pp. 819-823
• Burleigh, B.A., Host cell signaling and Trypanosoma cruzi invasion: Do all roads lead to lysosomes? (2005) Sci. STKE, 2005, pp. e36
• Combs, T.P., The adipocyte as an important target cell for Trypanosoma cruzi infection J. Biol. Chem, 280, pp. 24085-24094
• Tarleton, R.L., Reithinger, R., Urbina, J.A., Kitron, U., Gurtler, R.E., The challenges of Chagas disease - grim outlook or glimmer of hope (2007) PLoS Med, 4, pp. e332
• Gürtler, R.E., Kitron, U., Cecere, M.C., Segura, E.L., Cohen, J.E., Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina (2007) Proc. Natl. Acad. Sci. U. S. A, 104, pp. 16194-16199
• Pirard, M., Iihoshi, N., Boelaert, M., Basanta, P., Lopez, F., Van der Stuyft, P., The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region (2005) Transfusion, 45, pp. 554-561
• Avila, H.A., Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: Comparison with serology and xenodiagnosis (1993) J. Clin. Microbiol, 31, pp. 2421-2426
• Grevelink, S.A., Lerner, E.A., Leishmaniasis (1996) J Am Acad Dermatol, 34, pp. 257-272
• Marsden, P.D., Mucocutaneous leishmaniasis (1990) BMJ, 301, pp. 656-657
• Ramesh, V., Mukherjee, A., Post-kala-azar dermal leishmaniasis (1995) Int. J. Dermatol, 34, pp. 85-91
• Zijlstra, E.E., Musa, A.M., Khalil, E.A., el-Hassan, I.M., El-Hassan, A.M., Post-kala-azar dermal leishmaniasis (2003) Lancet Infect. Dis, 3, pp. 87-98
• Albrecht, H., Leishmaniosis - new perspectives on an underappreciated opportunistic infection (1998) AIDS, 12, pp. 2225-2226
• Ambroise-Thomas, P., Parasitic diseases and immunodeficiencies (2001) Parasitology, 122 (SUPPL.), pp. S65-S71
• Genaro, O., Vaccine for prophylaxis and immunotherapy, Brazil (1996) Clin. Dermatol, 14, pp. 503-512
• McConville, M.J., de Souza, D., Saunders, E., Likic, V.A., Naderer, T., Living in a phagolysosome; metabolism of Leishmania amastigotes (2007) Trends Parasitol, 23, pp. 368-375
• Denkers, E.Y., Butcher, B.A., Sabotage and exploitation in macrophages parasitized by intracellular protozoans (2005) Trends Parasitol, 21, pp. 35-41
• Grazia, C.M., Sutterwala, F.S., Trinchieri, G., Mosser, D.M., Ma, X., Suppression of Il-12 transcription in macrophages following Fc gamma receptor ligation (2001) J. Immunol, 166, pp. 4498-4506
• Marth, T., Kelsall, B.L., Regulation of interleukin-12 by complement receptor 3 signaling (1997) J. Exp. Med, 185, pp. 1987-1995
• Ghalib, H.W., IL-12 enhances Th1-type responses in human Leishmania donovani infections (1995) J. Immunol, 154, pp. 4623-4629
• Reed, S.G., Diagnosis of leishmaniasis (1996) Clin. Dermatol, 14, pp. 471-478
• Sadeghian, G., Momeni, A., Siadat, A.H., Usefi, P., Evaluation of leishmanin skin test and its relationship with the clinical form and duration of cutaneous leishmaniasis (2006) Dermatol. Online J, 12, p. 3
• Burns Jr., J.M., Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis (1993) Proc. Natl. Acad. Sci. U. S. A, 90, pp. 775-779
• Houghton, R.L., A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy (1998) J. Infect. Dis, 177, pp. 1339-1344
• Chava, A.K., Chatterjee, M., Sharma, V., Sundar, S., Mandal, C., Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-O-acetylated sialoglycans (2004) J. Infect. Dis, 189, pp. 1257-1264
• Reithinger, R., Dujardin, J.C., Molecular diagnosis of leishmaniasis: Current status and future applications (2007) J. Clin. Microbiol, 45, pp. 21-25
• da Costa, R.T., Standardization of a rapid immunochromatographic test with the recombinant antigens K39 and K26 for the diagnosis of canine visceral leishmaniasis (2003) Trans. R. Soc. Trop. Med. Hyg, 97, pp. 678-682
• De Luca, P.M., Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test (2003) Trans. R. Soc. Trop. Med. Hyg, 97, pp. 709-712
• Mazurek, G.H., Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States (2005) MMWR Recomm. Rep, 54, pp. 49-55
• Burri, C., Stich, G., Brun, R., Current chemotherapy of human african trypanosomiasis (2004) Trypanosomiasis, , I. Maudlin, P.H. Holmes, and M.A. Miles, editors. CABI Publishing. Wallingford, U.K
• Barrett, M.P., Boykin, D.W., Brun, R., Tidwell, R.R., Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease (2007) Br. J. Pharmacol, , In press
• Brun, R., Schumacher, R., Schmid, C., Kunz, C., Burri, C., The phenomenon of treatment failures in Human African Trypanosomiasis (2001) Trop. Med. Int. Health, 6, pp. 906-914
• Burri, C., Baltz, T., Giroud, C., Doua, F., Welker, H.A., Brun, R., Pharmacokinetic properties of the trypanocidal drug melarsoprol (1993) Chemotherapy, 39, pp. 225-234
• Schmid, C., Nkunku, S., Merolle, A., Vounatsou, P., Burri, C., Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness (2004) Lancet, 364, pp. 789-790
• Bisser, S., Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness (2007) J. Infect. Dis, 195, pp. 322-329
• Torr, S.J., Maudlin, I., Vale, G.A., Less is more: Restricted application of insecticide to cattle to improve the cost and efficacy of tsetse control (2007) Med Vet. Entomol, 21, pp. 53-64
• Kgori, P.M., Modo, S., Torr, S.J., The use of aerial spraying to eliminate tsetse from the Okavango Delta of Botswana (2006) Acta Trop, 99, pp. 184-199
• Castro, J.A., de Mecca, M.M., Bartel, L.C., Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis) (2006) Hum. Exp. Toxicol, 25, pp. 471-479
• Sosa, E.S., Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease (1998) Am. J. Trop. Med. Hyg, 59, pp. 526-529
• Viotti, R., Vigliano, C., Armenti, H., Segura, E., Treatment of chronic Chagas' disease with benznidazole: Clinical and serologic evolution of patients with long-term follow-up (1994) Am. Heart J, 127, pp. 151-162
• Viotti, R., Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial (2006) Ann. Intern. Med, 144, pp. 724-734
• de Castro, A.M., Luquetti, A.O., Rassi, A., Chiari, E., Galvao, L.M., Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection (2006) Parasitol. Res, 99, pp. 379-383
• Molina, J., Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts (2000) Antimicrob. Agents Chemother, 44, pp. 150-155
• Engel, J.C., Doyle, P.S., Hsieh, I., McKerrow, J.H., Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection (1998) J Exp. Med, 188, pp. 725-734
• Doyle, P.S., Zhou, Y.M., Engel, J.C., McKerrow, J.H., A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection (2007) Antimicrob. Agents Chemother, 51, pp. 3932-3939
• Dias, J.C., Silveira, A.C., Schofield, C.J., The impact of Chagas disease control in Latin America: A review (2002) Mem. Inst. Oswaldo Cruz, 97, pp. 603-612
• Gurtler, R.E., Effectiveness of residual spraying of peridomestic ecotopes with deltamethrin and permethrin on Triatoma infestans in rural western Argentina: A district-wide randomized trial (2004) Bull. World. Health Organ, 82, pp. 196-205
• Picollo, M.I., High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina (2005) J. Med. Entomol, 42, pp. 637-642
• Cohen, J.E., Gurtler, R.E., Modeling household transmission of American trypanosomiasis (2001) Science, 293, pp. 694-698
• Kroeger, A., Villegas, E., Ordonez-Gonzalez, J., Pabon, E., Scorza, J.V., Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials (2003) Am. J. Trop. Med. Hyg, 68, pp. 307-311
• Reithinger, R., Ceballos, L., Stariolo, R., Davies, C.R., Gurtler, R.E., Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars (2006) Am. J. Trop. Med. Hyg, 74, pp. 766-771
• Tarleton, R.L., Immune system recognition of Trypanosoma cruzi (2007) Curr. Opin. Immunol, 19, pp. 430-434
• Martin, D.L., CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes (2006) PLoS Pathog, 2, pp. e77
• Gurtler, R.E., Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina (2007) Parasitology, 134, pp. 69-82
• Olliaro, P.L., Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004 (2005) Lancet. Infect. Dis, 5, pp. 763-774
• Sundar, S., Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicentre study (2003) Clin. Infect. Dis, 37, pp. 800-804
• Bern, C., Liposomal amphotericin B for the treatment of visceral leishmaniasis (2006) Clin. Infect. Dis, 43, pp. 917-924
• Sundar, S., Jha, T.K., Thakur, C.P., Sinha, P.K., Bhattacharya, S.K., Injectable paromomycin for Visceral leishmaniasis in India (2007) N. Engl. J. Med, 356, pp. 2571-2581
• Armijos, R.X., Weigel, M.M., Calvopina, M., Mancheno, M., Rodriguez, R., Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis (2004) Acta Trop, 91, pp. 153-160
• Thakur, C.P., Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study (2000) Trans. R. Soc. Trop. Med. Hyg, 94, pp. 432-433
• Bhattacharya, S.K., Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis (2007) J. Infect. Dis, 196, pp. 591-598
• Soto, J., Berman, J., Treatment of New World cutaneous leishmaniasis with miltefosine (2006) Trans. R. Soc. Trop. Med. Hyg, 100 (SUPPL. 1), pp. S34-S40
• Engers, H.D., Bergquist, R., Modabber, F., Progress on vaccines against parasites (1996) Dev. Biol Stand, 87, pp. 73-84
• Khalil, E.A., Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan (2000) Lancet, 356, pp. 1565-1569
• Khalil, E.A., Safety and immunogenicity of an autoclaved Leishmania major vaccine (2000) East. Afr. Med. J, 77, pp. 468-470
• Mayrink, W., Immunotherapy as a treatment of American cutaneous leishmaniasis: Preliminary studies in Brazil (1992) Parassitologia, 34, pp. 159-165
• Jones, D.E., Elloso, M.M., Scott, P., Host susceptibility factors to cutaneous leishmaniasis (1998) Front. Biosci, 3, pp. D1171-D1180
• Lohoff, M., Gessner, A., Bogdan, C., Rollinghoff, M., The Th1/Th2 paradigm and experimental murine leishmaniasis (1998) Int Arch. Allergy. Immunol, 115, pp. 191-202
• Reed, S.G., Scott, P., T-cell and cytokine responses in leishmaniasis (1993) Curr. Opin. Immunol, 5, pp. 524-531
• Reiner, S.L., Locksley, R.M., The regulation of immunity to Leishmania major (1995) Annu. Rev. Immunol, 13, pp. 151-177
• Gorczynski, R.M., Nature of resistance to leishmaniasis in experimental rodents (1982) Dev. Comp. Immunol, 6, pp. 199-207
• Guler, M.L., Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development (1996) Science, 271, pp. 984-987
• Launois, P., Himmelrich, H., Tacchini-Cottier, F., Milon, G., Louis, J.A., New insight into the mechanisms underlying Th2 cell development and susceptibility to Leishmania major in BALB/c mice (1999) Microbes Infect, 1, pp. 59-64
• Scharton-Kersten, T., Afonso, L.C., Wysocka, M., Trinchieri, G., Scott, P., IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis (1995) J. Immunol, 154, pp. 5320-5330
• Nylen, S., Sacks, D., Interleukin-10 and the pathogenesis of human visceral leishmaniasis (2007) Trends Immunol, 28, pp. 378-384
• Coler, R.N., Reed, S.G., Second-generation vaccines against leishmaniasis (2005) Trends Parasitol, 21, pp. 244-249
• Hawn, T.R., Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway (2002) Microbes Infect, 4, pp. 763-771
• Kropf, P., Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major (2004) Infect Immun, 72, pp. 1920-1928
• Campos-Neto, A., Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease (2001) Infect. Immun, 69, pp. 4103-4108
• Coler, R.N., Goto, Y., Bogatzki, L., Raman, V., Reed, S.G., Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells (2007) Infect. Immun, 75, pp. 4648-4654
• Coler, R.N., Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis (2002) Infect. Immun, 70, pp. 4215-4225
• Skeiky, Y.A., Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant (2002) Vaccine, 20, pp. 3292-3303
• Ghalib, H., and Modabber, F. 2007. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol. Dis. 6:7; Croft, S.L., Sundar, S., Fairlamb, A.H., Drug resistance in leishmaniasis (2006) Clin. Microbiol. Rev, 19, pp. 111-126
• El-Sayed, N.M., Comparative genomics of trypanosomatid parasitic protozoa (2005) Science, 309, pp. 404-409
• Barry, D., (2007) Trypanosomes: After the genome, , Horizon Scientific Press. Norfolk, United Kingdom. 423 pp
• Stuart, K.D., Schnaufer, A., Ernst, N.L., Panigrahi, A.K., Complex management: RNA editing in trypanosomes (2005) Trends Biochem. Sci, 30, pp. 97-105
• Borst, P., Mechanisms of antigenic variation in African trypanosomes (1997) Behring. Inst. Mitt, pp. 1-15
• Berriman, M., The genome of the african trypanosome Trypanosoma brucei (2005) Science, 309, pp. 416-422
• Atwood 3rd, J.A., The Trypanosoma cruzi proteome (2005) Science, 309, pp. 473-476
• Heby, O., Persson, L., Rentala, M., Targeting the polyamine biosynthetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis (2007) Amino Acids, 33, pp. 359-366
• Opperdoes, F.R., Coombs, G.H., Metabolism of Leishmania: Proven and predicted (2007) Trends Parasitol, 23, pp. 149-158
• Ginger, M.L., Fairlamb, A.H., and Opperdoes, F.R. 2007. Comparative genomics of trypanosome metabolism. In Trypanosomes: after the genome. D. Barry, R. McCulloch, J. Mottram, and A. Acosta-Serrano, editors. Horizon Bioscience. Wynondham, United Kingdom. 373-416; Renslo, A.R., McKerrow, J.H., Drug discovery and development for neglected parasitic diseases (2006) Nat. Chem. Biol, 2, pp. 701-710
• Fairlamb, A.H., Target discovery and validation with special reference to trypanothione (2003) Drugs against parasitic diseases: R&D methodologies and issues, pp. 107-118. , A.H. Fairlamb, R.G. Ridley, and H.J. Vial, editors. TDR Publications. Geneva, Switzerland
• Frearson, J.A., Wyatt, P.A., Gilbert, I.H., Fairlamb, A.H., Target assessment for anti-parasitic drug discovery (2007) Trends Parasitol, 23, pp. 589-595
• Lee, S.H., Stephens, J.L., Englund, P.T., A fatty-acid synthesis mechanism specialized for parasitism (2007) Nat. Rev. Microbiol, 5, pp. 287-297
• de Macedo, C.S., Shams-Eldin, H., Smith, T.K., Schwarz, R.T., Azzouz, N., Inhibitors of glycosyl-phosphatidylinositol anchor biosynthesis (2003) Biochimie, 85, pp. 465-472
• Ferguson, M.A.J., The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness (1999) Biochim. Biophys. Acta, 1455, pp. 327-340
• Urbina, J.A., New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis) (2003) Expert Opinion on Therapeutic Patents, 13, pp. 661-669
• Nare, B., Luba, J., Hardy, L.W., Beverley, S.M., New approaches to Leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity (1997) Parasitology, 114, pp. S101-S110
• Ouellette, M., Pterin transport and metabolism in Leishmania and related trypanosomatid parasites (2002) Int. J. Parasitol, 32, pp. 385-398
• Krauth-Siegel, R.L., Bauer, H., Schirmer, H., Dithiol proteins as guardians of the intracellular redox milieu in parasites: Old and new drug targets in trypanosomes and malaria-causing plasmodia (2005) Angew. Chem. Int. Ed. Engl, 44, pp. 690-715
• Eastman, R.T., Buckner, F.S., Yokoyama, K., Gelb, M.H., Van Voorhis, W.C., Thematic review series: Lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation (2006) J. Lipid Res, 47, pp. 233-240
• Panethymitaki, C., Characterization and selective inhibition of myristoyl-CoA: Protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major (2006) Biochem. J, 396, pp. 277-285
• Werbovetz, K.A., Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis (2000) Curr. Med. Chem, 7, pp. 835-860
• El Kouni, M.H., Potential chemotherapeutic targets in the purine metabolism of parasites (2003) Pharmacol. Ther, 99, pp. 283-309
• Hammarton, T.C., Mottram, J.C., Doerig, C., The cell cycle of parasitic protozoa: Potential for chemotherapeutic exploitation (2003) Prog. Cell Cycle Res, 5, pp. 91-101
• Balana-Fouce, R., Redondo, C.M., Perez-Pertejo, Y., Diaz-Gonzalez, R., Reguera, R.M., Targeting atypical trypanosomatid DNA topoisomerase I (2006) Drug Discov. Today, 11, pp. 733-740
• Deng, J., Ernst, N.L., Turley, S., Stuart, K.D., Hol, W.G., Structural basis for UTP specificity of RNA editing TUTases from Trypanosoma brucei (2005) EMBO J, 24, pp. 4007-4017
• Schnaufer, A., An RNA ligase essential for RNA editing and survival of the bloodstream form of Trypanosoma brucei (2001) Science, 291, pp. 2159-2162
• Hopkins, A.L., Groom, C.R., The druggable genome (2002) Nat. Rev. Drug Discov, 1, pp. 727-730
• Nwaka, S., Hudson, A., Innovative lead discovery strategies for tropical diseases (2006) Nat. Rev. Drug Discov, 5, pp. 941-955
• Development and evaluation of new diagnostic tests for human African trypanosomiasis (2006) Wkly. Epidemiol. Rec, 81, pp. 59-60
• Bhattacharya, S.K., Sur, D., Sinha, P.K., Karbwang, J., Elimination of leishmaniasis (kalaazar) from the Indian subcontinent is technically feasible and operationally achievable (2006) Indian J. Med. Res, 123, pp. 195-196
• Enserink, M., Entomology. Welcome to Ethiopia's fly factory (2007) Science, 317, pp. 310-313
• Agranoff, D., Stich, A., Abel, P., Krishna, S., Proteomic fingerprinting for the diagnosis of human African trypanosomiasis (2005) Trends Parasitol, 21, pp. 154-157
• . 2002. Manson's tropical diseases. W.B. Saunders/Elsevier. Edinburgh, United Kingdom. 1864 pp; Lane, R.P., Crosskey, R.W., (1993) Medical insects and arachnids, , Chapman & Hall. London, United Kingdom. 723 pp
• . 2004. The World Health Report 2004: changing history. WHO. Geneva, Switzerland. 167 pp; Maudlin, I., Holmes, P.H., Miles, M.A., (2004) The Trypanosomiases, , CABI Publishing. Wallingford, United Kingdom. 632 pp
• (2001) Report on African Trypanosomiasis (sleeping sickness), , Scientific Working Group, WHO. Geneva, Switzerland. 1-169
• (2004) Report on Leishmaniasis, , Scientific Working Group, WHO. Geneva, Switzerland. 137 pp
• Kuzoe, F.A.S., Shofield, C.J., (2004) Strategic review of traps and targets of tsetse and African typanosomiasis control, , WHO. Geneva, Switzerland. 58 pp

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------